A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]

Lipoprotein Disorder Clinical Trial

Official title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults With Elevated Lipoprotein(a)

Status Active, not recruiting

Clinical Trial Summary

The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts about 20 months.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Lipoprotein Disorder

Clinical Trial Details

NCT number	NCT05565742
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	October 20, 2022
Completion date	October 18, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05563246` - A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events	Phase 2
Recruiting	`NCT04156997` - Extreme Lipids Repository
Recruiting	`NCT05496790` - Role of LipoprotEin(a) in CardiovascuLar Diseases and Premature Acute Coronary Syndromes - (RELACS) Study
Not yet recruiting	`NCT05081440` - A Multi-center, Prospective, Observational Study to Describe the siTuation of Blood Lipid mAnagement Among the Population With hypeRtension and/or Type 2 diabeTes in Community Health Center